Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.54
MDT's Cash to Debt is ranked lower than
75% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. MDT: 0.54 )
Ranked among companies with meaningful Cash to Debt only.
MDT' s 10-Year Cash to Debt Range
Min: 0.21  Med: 0.85 Max: 7.76
Current: 0.54
0.21
7.76
Equity to Asset 0.50
MDT's Equity to Asset is ranked lower than
68% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. MDT: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
MDT' s 10-Year Equity to Asset Range
Min: 0.48  Med: 0.58 Max: 0.79
Current: 0.5
0.48
0.79
Interest Coverage 5.65
MDT's Interest Coverage is ranked lower than
88% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. MDT: 5.65 )
Ranked among companies with meaningful Interest Coverage only.
MDT' s 10-Year Interest Coverage Range
Min: 5.65  Med: 22.05 Max: 352.69
Current: 5.65
5.65
352.69
F-Score: 4
Z-Score: 2.45
M-Score: -1.90
WACC vs ROIC
11.08%
9.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 18.59
MDT's Operating margin (%) is ranked higher than
87% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. MDT: 18.59 )
Ranked among companies with meaningful Operating margin (%) only.
MDT' s 10-Year Operating margin (%) Range
Min: 16.71  Med: 28.83 Max: 66.79
Current: 18.59
16.71
66.79
Net-margin (%) 13.20
MDT's Net-margin (%) is ranked higher than
83% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. MDT: 13.20 )
Ranked among companies with meaningful Net-margin (%) only.
MDT' s 10-Year Net-margin (%) Range
Min: 11.03  Med: 19.66 Max: 22.78
Current: 13.2
11.03
22.78
ROE (%) 10.17
MDT's ROE (%) is ranked higher than
69% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. MDT: 10.17 )
Ranked among companies with meaningful ROE (%) only.
MDT' s 10-Year ROE (%) Range
Min: 7.36  Med: 20.87 Max: 32.99
Current: 10.17
7.36
32.99
ROA (%) 4.84
MDT's ROA (%) is ranked higher than
65% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. MDT: 4.84 )
Ranked among companies with meaningful ROA (%) only.
MDT' s 10-Year ROA (%) Range
Min: 3.7  Med: 11.74 Max: 23.74
Current: 4.84
3.7
23.74
ROC (Joel Greenblatt) (%) 62.17
MDT's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. MDT: 62.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 51.21  Med: 70.49 Max: 161.75
Current: 62.17
51.21
161.75
Revenue Growth (3Y)(%) 6.20
MDT's Revenue Growth (3Y)(%) is ranked higher than
62% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. MDT: 6.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.2  Med: 12.80 Max: 17.9
Current: 6.2
4.2
17.9
EBITDA Growth (3Y)(%) 0.50
MDT's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. MDT: 0.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MDT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -15.5  Med: 9.90 Max: 45.4
Current: 0.5
-15.5
45.4
EPS Growth (3Y)(%) -9.20
MDT's EPS Growth (3Y)(%) is ranked lower than
61% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. MDT: -9.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MDT' s 10-Year EPS Growth (3Y)(%) Range
Min: -9.2  Med: 13.50 Max: 27.1
Current: -9.2
-9.2
27.1
» MDT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MDT Guru Trades in Q3 2014

Ruane Cunniff 9,700 sh (New)
Ray Dalio 27,045 sh (New)
Andreas Halvorsen 1,841,414 sh (New)
Joel Greenblatt 496,211 sh (+5179.96%)
HOTCHKIS & WILEY 3,230,958 sh (+67.19%)
Robert Olstein 142,000 sh (+23.48%)
Paul Tudor Jones 11,500 sh (+9.52%)
Ken Fisher 6,165 sh (+2.49%)
Bill Nygren 4,690,000 sh (+1.85%)
Dodge & Cox 8,864,623 sh (+1.00%)
John Buckingham 19,152 sh (+0.75%)
James Barrow 32,479,848 sh (+0.43%)
Pioneer Investments 976,081 sh (unchged)
Mario Gabelli 40,000 sh (unchged)
John Keeley 33,460 sh (unchged)
Vanguard Health Care Fund 12,402,000 sh (unchged)
Chuck Royce Sold Out
Scott Black Sold Out
PRIMECAP Management 29,535,573 sh (-0.23%)
Jeff Auxier 146,345 sh (-1.99%)
Jim Simons 2,200,400 sh (-4.86%)
Bill Frels 3,768,038 sh (-9.12%)
First Eagle Investment 1,790,484 sh (-14.67%)
Diamond Hill Capital 3,703,791 sh (-19.58%)
Steven Cohen 265,300 sh (-71.56%)
Jeremy Grantham 551,007 sh (-90.01%)
» More
Q4 2014

MDT Guru Trades in Q4 2014

John Hussman 200,000 sh (New)
Steven Cohen 658,900 sh (+148.36%)
Ray Dalio 36,632 sh (+35.45%)
Vanguard Health Care Fund 13,047,000 sh (+5.20%)
James Barrow 32,638,454 sh (+0.49%)
Ken Fisher 6,193 sh (+0.45%)
Bill Nygren 4,690,000 sh (unchged)
Jim Simons Sold Out
Andreas Halvorsen Sold Out
Jeff Auxier 145,895 sh (-0.31%)
Dodge & Cox 8,817,773 sh (-0.53%)
John Buckingham 19,051 sh (-0.53%)
Diamond Hill Capital 3,678,388 sh (-0.69%)
HOTCHKIS & WILEY 3,207,884 sh (-0.71%)
John Keeley 33,180 sh (-0.84%)
Robert Olstein 134,000 sh (-5.63%)
Bill Frels 3,396,496 sh (-9.86%)
Pioneer Investments 788,292 sh (-19.24%)
First Eagle Investment 1,236,314 sh (-30.95%)
PRIMECAP Management 18,578,166 sh (-37.10%)
Ruane Cunniff 4,700 sh (-51.55%)
Paul Tudor Jones 3,800 sh (-66.96%)
Mario Gabelli 10,000 sh (-75.00%)
Joel Greenblatt 19,608 sh (-96.05%)
Jeremy Grantham 4,046 sh (-99.27%)
Steven Romick -2,425,900 sh (-9999.00%)
» More
Q1 2015

MDT Guru Trades in Q1 2015

Louis Moore Bacon 25,233 sh (New)
Ronald Muhlenkamp 173,653 sh (New)
Caxton Associates 30,000 sh (New)
First Pacific Advisors 2,147,307 sh (New)
Jeremy Grantham 7,402,676 sh (+182862.83%)
Mario Gabelli 66,282 sh (+562.82%)
Ray Dalio 172,832 sh (+371.81%)
Pioneer Investments 2,760,285 sh (+250.16%)
Paul Tudor Jones 11,800 sh (+210.53%)
Joel Greenblatt 37,793 sh (+92.74%)
HOTCHKIS & WILEY 5,753,016 sh (+79.34%)
Vanguard Health Care Fund 18,885,933 sh (+44.75%)
John Keeley 40,512 sh (+22.10%)
Ken Fisher 6,717 sh (+8.46%)
Ruane Cunniff 4,880 sh (+3.83%)
John Buckingham 19,377 sh (+1.71%)
John Hussman 200,000 sh (unchged)
Robert Olstein 134,000 sh (unchged)
Bill Nygren 4,690,000 sh (unchged)
Dodge & Cox 8,696,577 sh (-1.37%)
James Barrow 31,889,163 sh (-2.30%)
Diamond Hill Capital 3,566,702 sh (-3.04%)
Bill Frels 3,254,448 sh (-4.18%)
PRIMECAP Management 17,545,221 sh (-5.56%)
First Eagle Investment 937,172 sh (-24.20%)
Jeff Auxier 45,530 sh (-68.79%)
Steven Cohen 136,200 sh (-79.33%)
Steven Romick 2,020,579 sh (-183.29%)
» More
Q2 2015

MDT Guru Trades in Q2 2015

John Burbank 2,694 sh (New)
Steven Cohen 596,400 sh (+337.89%)
Jeff Auxier 139,583 sh (+206.57%)
John Buckingham 20,357 sh (+5.06%)
Jeremy Grantham 7,545,614 sh (+1.93%)
First Pacific Advisors 2,169,396 sh (+1.03%)
Ronald Muhlenkamp 173,750 sh (+0.06%)
John Keeley 40,520 sh (+0.02%)
Vanguard Health Care Fund 18,885,933 sh (unchged)
Steven Romick 2,020,579 sh (unchged)
Ruane Cunniff 4,880 sh (unchged)
Robert Olstein 134,000 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Caxton Associates Sold Out
Diamond Hill Capital 3,550,528 sh (-0.45%)
Mario Gabelli 65,949 sh (-0.50%)
James Barrow 31,616,685 sh (-0.85%)
Bill Frels 3,213,444 sh (-1.26%)
HOTCHKIS & WILEY 5,619,508 sh (-2.32%)
Ken Fisher 6,445 sh (-4.05%)
PRIMECAP Management 16,396,096 sh (-6.55%)
Dodge & Cox 8,011,783 sh (-7.87%)
Bill Nygren 4,190,000 sh (-10.66%)
John Hussman 175,000 sh (-12.50%)
Pioneer Investments 2,376,902 sh (-13.89%)
Ray Dalio 85,132 sh (-50.74%)
First Eagle Investment 12,735 sh (-98.64%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Medtronic PLC

Bill Frels Comments on Medtronic Inc - Oct 20, 2014

Healthcare company Medtronic, Inc. (MDT) detracted slightly from performance during the period. Pending a shareholder vote later this year or in 2015, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Your Growth Fund portfolio managers are pleased to report that we have completed our valuation for Medtronic. As of October 7, 2014 we believe combined Medtronic/Covidien to be $8 per share more valuable than shares of Medtronic alone.

As of September 30, 2014, the market value of the Growth Fund’s holding in Medtronic was $24 per share greater than its cost basis. We estimate that our typical shareholder, that holds the Growth Fund in a taxable amount, will experience about a $6.00 per share tax liability. We do not offer tax advice; each shareholder should consult a tax advisor about his/her particular circumstance. Providing that there are no significant changes, our current thinking leads us to believe that voting for the merger is in our shareholders’ best interest. We will keep you posted as the voting date is finalized or if we learn of any other developments regarding the merger plans.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

Bill Frels Comments on Medtronic Inc - Jul 31, 2014

Healthcare company Medtronic, Inc. (MDT) also contributed to performance, gaining 3.61% and 11.10% for the second quarter and first six months, respectively. Pending a shareholder vote later this year or in 2015, however, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Once completed, the merger will create a taxable event for Fund shareholders who will realize a long-term capital gain estimated at $60 million or $1.50 a share.

From Bill Frels (Trades, Portfolio)’ Mairs & Power Growth Fund Second Quarter 2014 Commentary.

Check out Bill Frels latest stock trades

Bill Frels Comments on Medtronic Inc - Jun 25, 2014

Healthcare company Medtronic, Inc. (MDT) also finished the quarter as a top five contributor to the Fund, gaining 7.23%. While emerging market revenue proved scarce for most industries during the quarter, Medtronic increased its share of revenue from the developing world by 15%, which represented 12% of the company’s revenue.



From Bill Frels' Mairs & Power Balance Fund First Quarter 2014 Commentary.



Check out Bill Frels latest stock trades

Top Ranked Articles about Medtronic PLC

Hotchkis & Wiley Adds to Banking, Insurance Stakes
In its 35-year existence, value investor HOTCHKIS & WILEY has built its reputation on identifying undervalued companies that have great growth potential. But in the first quarter, most of its emphasis was on well-established companies, especially those in banking and insurance. Read more...
Steven Romick Shorts Alibaba, Medtronic in Q4
Steven Romick (Trades, Portfolio) is the portfolio manager of the long-short FPA Crescent Fund. During the fourth quarter, Romick shorted four additional positions, bringing the fund’s total number of short positions to 29. Read more...
Bill Frels Comments on Medtronic Inc
Healthcare company Medtronic, Inc. (MDT) detracted slightly from performance during the period. Pending a shareholder vote later this year or in 2015, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Your Growth Fund portfolio managers are pleased to report that we have completed our valuation for Medtronic. As of October 7, 2014 we believe combined Medtronic/Covidien to be $8 per share more valuable than shares of Medtronic alone. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.21
MDT's P/E(ttm) is ranked higher than
53% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. MDT: 26.21 )
Ranked among companies with meaningful P/E(ttm) only.
MDT' s 10-Year P/E(ttm) Range
Min: 10.14  Med: 20.55 Max: 43.51
Current: 26.21
10.14
43.51
Forward P/E 16.45
MDT's Forward P/E is ranked higher than
74% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.31 vs. MDT: 16.45 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.50
MDT's PE(NRI) is ranked higher than
53% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 28.40 vs. MDT: 27.50 )
Ranked among companies with meaningful PE(NRI) only.
MDT' s 10-Year PE(NRI) Range
Min: 10.13  Med: 20.57 Max: 43.51
Current: 27.5
10.13
43.51
P/B 1.87
MDT's P/B is ranked higher than
66% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. MDT: 1.87 )
Ranked among companies with meaningful P/B only.
MDT' s 10-Year P/B Range
Min: 1.86  Med: 3.19 Max: 6.52
Current: 1.87
1.86
6.52
P/S 3.84
MDT's P/S is ranked lower than
63% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. MDT: 3.84 )
Ranked among companies with meaningful P/S only.
MDT' s 10-Year P/S Range
Min: 1.92  Med: 3.56 Max: 6.78
Current: 3.84
1.92
6.78
PFCF 18.26
MDT's PFCF is ranked higher than
78% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 33.52 vs. MDT: 18.26 )
Ranked among companies with meaningful PFCF only.
MDT' s 10-Year PFCF Range
Min: 9.2  Med: 14.74 Max: 70.14
Current: 18.26
9.2
70.14
POCF 16.15
MDT's POCF is ranked higher than
66% of the 157 Companies
in the Global Medical Devices industry.

( Industry Median: 22.08 vs. MDT: 16.15 )
Ranked among companies with meaningful POCF only.
MDT' s 10-Year POCF Range
Min: 8.13  Med: 12.79 Max: 32.39
Current: 16.15
8.13
32.39
EV-to-EBIT 27.74
MDT's EV-to-EBIT is ranked lower than
67% of the 159 Companies
in the Global Medical Devices industry.

( Industry Median: 21.34 vs. MDT: 27.74 )
Ranked among companies with meaningful EV-to-EBIT only.
MDT' s 10-Year EV-to-EBIT Range
Min: 8.8  Med: 16.60 Max: 34.4
Current: 27.74
8.8
34.4
PEG 13.75
MDT's PEG is ranked lower than
85% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. MDT: 13.75 )
Ranked among companies with meaningful PEG only.
MDT' s 10-Year PEG Range
Min: 1.06  Med: 1.87 Max: 14.56
Current: 13.75
1.06
14.56
Shiller P/E 22.08
MDT's Shiller P/E is ranked higher than
66% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 32.28 vs. MDT: 22.08 )
Ranked among companies with meaningful Shiller P/E only.
MDT' s 10-Year Shiller P/E Range
Min: 12.1  Med: 20.35 Max: 46.74
Current: 22.08
12.1
46.74
Current Ratio 3.36
MDT's Current Ratio is ranked higher than
62% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. MDT: 3.36 )
Ranked among companies with meaningful Current Ratio only.
MDT' s 10-Year Current Ratio Range
Min: 0.88  Med: 2.45 Max: 4.52
Current: 3.36
0.88
4.52
Quick Ratio 2.98
MDT's Quick Ratio is ranked higher than
67% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. MDT: 2.98 )
Ranked among companies with meaningful Quick Ratio only.
MDT' s 10-Year Quick Ratio Range
Min: 0.69  Med: 2.02 Max: 4.09
Current: 2.98
0.69
4.09
Days Inventory 124.64
MDT's Days Inventory is ranked higher than
53% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 129.48 vs. MDT: 124.64 )
Ranked among companies with meaningful Days Inventory only.
MDT' s 10-Year Days Inventory Range
Min: 132.14  Med: 155.34 Max: 232.97
Current: 124.64
132.14
232.97
Days Sales Outstanding 92.09
MDT's Days Sales Outstanding is ranked lower than
66% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.92 vs. MDT: 92.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDT' s 10-Year Days Sales Outstanding Range
Min: 64.09  Med: 82.62 Max: 92.09
Current: 92.09
64.09
92.09

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.86
MDT's Dividend Yield is ranked higher than
59% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. MDT: 1.86 )
Ranked among companies with meaningful Dividend Yield only.
MDT' s 10-Year Dividend Yield Range
Min: 0.59  Med: 1.82 Max: 2.93
Current: 1.86
0.59
2.93
Dividend Payout 0.51
MDT's Dividend Payout is ranked higher than
70% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 0.35 vs. MDT: 0.51 )
Ranked among companies with meaningful Dividend Payout only.
MDT' s 10-Year Dividend Payout Range
Min: 0.14  Med: 0.25 Max: 0.51
Current: 0.51
0.14
0.51
Dividend growth (3y) 7.90
MDT's Dividend growth (3y) is ranked higher than
59% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. MDT: 7.90 )
Ranked among companies with meaningful Dividend growth (3y) only.
MDT' s 10-Year Dividend growth (3y) Range
Min: 7.6  Med: 15.50 Max: 26
Current: 7.9
7.6
26
Yield on cost (5-Year) 2.75
MDT's Yield on cost (5-Year) is ranked higher than
69% of the 184 Companies
in the Global Medical Devices industry.

( Industry Median: 1.63 vs. MDT: 2.75 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MDT' s 10-Year Yield on cost (5-Year) Range
Min: 0.87  Med: 2.69 Max: 4.33
Current: 2.75
0.87
4.33
Share Buyback Rate -1.50
MDT's Share Buyback Rate is ranked higher than
62% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: -4.20 vs. MDT: -1.50 )
Ranked among companies with meaningful Share Buyback Rate only.
MDT' s 10-Year Share Buyback Rate Range
Min: 2.6  Med: 0.30 Max: -8.3
Current: -1.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.23
MDT's Price/Projected FCF is ranked higher than
76% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. MDT: 1.23 )
Ranked among companies with meaningful Price/Projected FCF only.
MDT' s 10-Year Price/Projected FCF Range
Min: 0.77  Med: 1.55 Max: 6.95
Current: 1.23
0.77
6.95
Price/DCF (Earnings Based) 2.42
MDT's Price/DCF (Earnings Based) is ranked lower than
67% of the 15 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. MDT: 2.42 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.09
MDT's Price/Median PS Value is ranked lower than
59% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. MDT: 1.09 )
Ranked among companies with meaningful Price/Median PS Value only.
MDT' s 10-Year Price/Median PS Value Range
Min: 0.69  Med: 1.66 Max: 3.55
Current: 1.09
0.69
3.55
Earnings Yield (Greenblatt) (%) 3.64
MDT's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. MDT: 3.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.9  Med: 6.00 Max: 11.3
Current: 3.64
2.9
11.3
Forward Rate of Return (Yacktman) (%) 7.30
MDT's Forward Rate of Return (Yacktman) (%) is ranked higher than
58% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 4.79 vs. MDT: 7.30 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MDT' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 7  Med: 15.30 Max: 23.8
Current: 7.3
7
23.8

Analyst Estimate

Apr16 Apr17 Apr18
Revenue(Mil) 28,843 29,982 30,921
EPS($) 4.35 4.82 5.33
EPS without NRI($) 4.35 4.82 5.33

Business Description

Industry: Medical Devices » Medical Devices
Compare:SYK, SMA, ZMH, STJ, EW » details
Traded in other countries:2M6.Germany, MDT.Argentina, 0QYG.UK, MDT.Switzerland, MDT N.Mexico,
Medtronic PLC was founded in 1949, incorporated as a Minnesota corporation in 1957. The Company is a medical technology company - alleviating pain, restoring health, and extending life for millions of people around the world. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat and diabetes conditions. The Company functions in four operating segments that manufacture and sell device-based medical therapies: Cardiac and Vascular Group; Minimally Invasive Therapies Group; Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group includes Cardiac Rhythm Disease Management that develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRDM devices, and an integrated health solutions business; Coronary which includes therapies to treat coronary artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, including a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories; The Structural Heart business offers a comprehensive line of products and therapies to treat a variety of heart valve disorders. The Endovascular business is comprised of a comprehensive line of products and therapies to treat aortic disease (such as aneurysms, dissections, and transections) as well as peripheral vascular disease (PVD). Its products include endovascular stent graft systems, peripheral stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart. The Minimally Invasive Therapies Group is composed of the Surgical Solutions and Patient Monitoring & Recovery divisions. With a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications, the group looks to enhance patient outcomes through minimally invasive solutions. The Restorative Therapies Group includes Spine business which develops, manufactures, and markets a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its products and therapies treat a variety of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumors, fractures of the spine, and stenosis. Its Spine business also provides biologic solutions for the orthopedic and dental markets. Its Neuromodulation business includes implantable neurostimulation and targeted drug delivery systems for the management o
» More Articles for MDT

Headlines

Articles On GuruFocus.com
In Today’s Overheated Market Control Risk in Your Retirement Portfolios with Sound Valuation Aug 20 2015 
JFS Wealth Advisors LLC Buys Alliance Holdings in Q2 2015 Aug 05 2015 
Hotchkis & Wiley Add to Banking, Insurance Stakes Jun 26 2015 
Looking Ahead of Wall Street: Ambarella Inc., Dollar General Corp., Medtronic PLC Jun 01 2015 
First Pacific Advisors Purchase New Positions During 1QFY15 May 22 2015 
My Stock Watch List For April 2015 Apr 05 2015 
Mairs & Power Balanced Fund Q4 2014 Commentary Mar 31 2015 
Freedom Fund Update – March 2015 Mar 02 2015 
Medtronic (MDT) Momentum at All-Time-High Levels, Knowles (KN) Rating Boosted Feb 21 2015 
Medtronic Q3 Earnings 2015 Exceeds Market Expectations Feb 19 2015 

More From Other Websites
Business Watch: News Digest Sep 03 2015
Edited Transcript of MDT earnings conference call or presentation 3-Sep-15 12:00pm GMT Sep 03 2015
Medtronic Revenue Boosted by Covidien Acquisition Sep 03 2015
Medtronic sales surge as rise in U.S. surgeries drives demand Sep 03 2015
Early movers: SLB, LULU, EBAY, MDT, JOY & more Sep 03 2015
Cramer: Medtronic to Go Higher, Joy Global to Go Lower Sep 03 2015
Medtronic Beats on Q1 Earnings, Covidien Synergy on Track Sep 03 2015
Medtronic Q1 Beats Estimates; Guidance Affirmed Sep 03 2015
Q1 Revenue Lifts Medtronic Over Low Earnings Bar Sep 03 2015
Cramer's Mad Dash: Medtronic is the star Sep 03 2015
Covidien deal, heart devices boost Medtronic's fortunes Sep 03 2015
Medtronic (MDT) Tops Q1 Earnings and Revenue Estimates Sep 03 2015
Medtronic (MDT) Stock Rallies as Earnings Exceed Estimates, Jim Cramer Weighs In Sep 03 2015
Medtronic PLC Earnings Call scheduled for 8:00 am ET today Sep 03 2015
Medtronic Profit Beats Estimates on New Heart Device Demand Sep 03 2015
Medtronic profit jumps 47 pct Sep 03 2015
Medtronic Reports First Quarter Financial Results Sep 03 2015
7:21 am Medtronic beats by $0.02, beats on revs; reaffirms FY16 EPS guidance Sep 03 2015
MEDTRONIC PLC Files SEC form 8-K, Results of Operations and Financial Condition Sep 03 2015
Medtronic Reports First Quarter Financial Results Sep 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK